Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - February 21, 2025
Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials
SPTX Neutral Sentiment
Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials
Key Takeaway: The article discusses the role of clinician-administered assessments in recent clinical trials for major depressive disorder (MDD). It highlights the influence of these assessments on placebo responses. The content suggests an ongoing exploration of methodologies in MDD trials, but does not provide specific outcomes or data.
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is the focus of the article?
The article focuses on clinician-administered assessments and their impact on placebo responses in MDD clinical trials.
When was the article published?
The article was published on February 21, 2025.
What condition is being discussed in the trials?
The trials discussed in the article pertain to major depressive disorder (MDD).